ACOG | GenomeWeb

ACOG

The ob-gyn groups issued a statement warning that insurers' prior authorization requirements will hinder patients' access to much needed care.

"Conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population," the committee wrote.

This article has been updated to include comments from CytoGenX.
CytoGenX, a Stony Brook, NY-based medical genetic testing services company, recently introduced chromosomal microarray analysis for a number of different indications.

Counsyl has begun offering a next-generation sequencing-based expanded carrier screening test to early access users with a full commercial launch planned for the end of the second quarter this year.

It remains to be seen whether a market for PCR-based fragile X population screening will soon develop, since mandating newborn testing may be highly dependent on the development of a difference-making therapeutic; and carrier screening will likely continue to rely on a case-by-case cost-benefit analysis.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.